Results 151 to 160 of about 75,380 (266)

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

Disseminated Histoplasmosis: An Unusual Finding at ROSE

open access: yesDiagnostic Cytopathology, Volume 54, Issue 6, Page E146-E148, June 2026.
ABSTRACT We describe an unusual case in which disseminated histoplasmosis was suspected at the time of of rapid on‐site assessment (ROSE) performed during endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA). The patient was a renal transplant recipient with fever, mild anemia, bilateral lung infiltrates and mediastinal ...
Erika E. Doxtader   +2 more
wiley   +1 more source

Cytologic Findings in Esophageal Perforation: An Institutional Experience With Pleural Fluid Specimens

open access: yesDiagnostic Cytopathology, Volume 54, Issue 6, Page 429-435, June 2026.
ABSTRACT Introduction Esophageal perforation (EP) is a rare but life‐threatening condition, and most cases are due to iatrogenic causes. The rest occur spontaneously, due to malignancies, or trauma. The mortality rates can approach 50%, and delayed diagnosis of EP exacerbates patient outcomes.
Mason Marshall   +3 more
wiley   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy